On February 6, 2026, Novakand reported that the Company had entered into an a share purchase agreement with the shareholders of SVF concerning a reverse takeover. The proposed Transaction suggests that Novakand acquires all shares in SVF through an issue in kind (Sv. apportemission), where payment will be made in the form of newly issued shares in Novakand.

Per Nasdaq’s rulebook, the Transaction will mean that Novakand undergoes substantial changes post the Transaction and therefor requires a new listing process. According to the share purchase agreement, the completion of the Transaction is therefore conditional upon, amongst other things, Nasdaq’s approval of the combined company for the continued listing. The Company today announces that the application to Nasdaq has been submitted.

The Transaction is also conditional upon approval of the Transaction from an Extraordinary General Meeting (“EGM”) in Novakand and receipt of regulatory approval from the Swedish Inspectorate of Strategic Products. A description of the combined company’s business will be provided on Novakand’s website well in advance of the EGM. For more information about the Transaction, please refer to the press release issued by the Company on February 6, 2026.

In addition, the Company announces that going forward the Company’s regulatory press releases, including financial reports, will only be released in Swedish.

About Novakand Pharma AB
Novakand Pharma is a clinical stage biotech developing a new class of small molecule drugs with an immune cell modulating mode-of-action. The stock is traded on Nasdaq First North Premier. Redeye AB is the company’s Certified Adviser and can be contacted at: [email protected].

For further information:
Visit the companies’ websites at: www.novakand.com and www.svfvaccines.com
or contact: [email protected].